Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients With Type 2 Diabetes (SURPASS-1): A Double-blind, Randomised, Phase 3 Trial
Changes Appetite Semaglutide delays the rate at which the stomach empties, which results in a slower absorption of nutrients, including glucose
Our customer service team will reach out for more information as needed
Dysesthesia reported in about 20.9% at the highest dose
1: 16888 & 25263 Deerochanawong C, Home PD, Alberti KGMM
Individuals seeking medically guided weight loss Adults struggling with appetite control or cravings Those with a BMI in the overweight or obese range Individuals with insulin resistance or prediabetes (pending physician approval) Patients who have plateaued with diet and exercise alone People committed to combining medication with lifestyle changes Anyone wanting a structured, physician-led program with ongoing support Who Should Avoid GLP